GlobeNewswire

OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS

Share


COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE

OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS

The deadline for submission of all tenders is January 10th, 2020 before 04:00pm  

Paris and Boston, December 6th,  2019 – 05h45pm  CET - Neovacs (Euronext Growth Paris : ALNEV) announces the launch of a call for tender opened from now until January 10th, 2020 before 4:00 pm, to provide a continuation plan through partners or investors (articles L.626-1 and L.626-3 of the French Commercial code) or a sale plan by one or more buyers (Articles L.642-1 et seq. of the French Commercial Code).

Candidates are invited to submit their offer before January 10th, 2020 at 04:00pm at the following law office:  SELARL 2M and associates, to Maître Carole Martinez, judicial administrator, 22 rue de l'Arcade 75008 Paris, France. Email: a.dekoninck@aj-2m.com

Access to information for auditing the company (electronic data room), will be granted upon reasoned written request to the judicial administrator along with the appropriate financial, industrial or commercial capacity proofs.

As a reminder, on November 26th, 2019 the Commercial Court of Paris decided the opening of reorganization proceedings of the company, as requested by Neovacs (press release of November 27th, 2019).

Neovacs is a French biotech company listed on Euronext Growth since 2010. The Company is focused on therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology named Kinoid™, patented until 2038, induces a polyclonal immune response, applicable in several indications. Neovacs has developed the IFNα KINOID to treat lupus in a clinical phase IIb study, the main study is now ended and the full results have been presented at the 13th international Lupus Congress 2019. The Company also carries out preclinical work on IL-4/ IL-13 Kinoid, another therapeutic vaccine for the treatment of allergies. The aim of this "KINOID approach" is to enable patients to better cope with a life-long treatment that would be more effective.  For more information : www.neovacs.fr

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

HOYLU AB: HOYLU ADDS WORKSPACE VOTING AND TIMER FEATURES28.9.2020 08:45:00 CESTPress release

Stockholm, Sweden, September 28, 2020 – Hoylu, a leader in visual collaboration solutions for distributed teams, announced today the immediate addition of two powerful new features to Hoylu workspaces for all users. Voting and Timer are available now to all registered users of Hoylu, and expand functionality for new and existing workspaces. Available as part of every workspace, users can now place votes using emojis, icons and symbols on notes and tasks. This functionality enhances project planning, retrospectives, brainstorming and task management by offering engaging user participation that can help guide workplace decisions. Voting objects are fully flexible and quickly tallies items for ease of use by project managers or workspace owners. The timer functionality allows synchronization of tasks and projects by allowing users to add a flexible timer to any workspace that counts down to a deadline for all users. Timers persist outside of active use, making it easy for short or long-te

HOYLU AB: HOYLU LÄGGER TILL RÖSTNING OCH TIMER FUNKTIONER I ARBETSYTORNA28.9.2020 08:45:00 CESTPressemelding

Stockholm, Sverige, 28 september 2020 – Hoylu, ledande inom visuella samarbetslösningar för distribuerade team, tillkännagav idag det omedelbara tillskottet av två kraftfulla nya funktioner i Hoylu-workspaces för alla användare. Voting (röstning) och Timer är tillgängliga nu för alla registrerade Hoylu-användare, och utökar därmed funktionaliteten för nya och befintliga arbetsytor. Tillgängliga som en del av varje arbetsyta, kan användare nu placera röster med emojis, ikoner och symboler på anteckningar och uppgifter. Denna funktionalitet förbättrar projektplanering, retrospektiv, brainstorming och uppgiftshantering genom att erbjuda engagerande användardeltagande som kan underlätta och ge vägledning i olika beslut på arbetsplatsen. Röstningsobjekten är fullt flexibla och objekten stämmer snabbt vilket förenklar användningen av funktionerna för projektledarna eller arbetsytornas ägare. Timerfunktionen tillåter synkronisering av uppgifter och projekt genom att användarna kan lägga till

Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer28.9.2020 07:15:00 CESTPress release

Basel, Switzerland, September 28, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the phase 1/2 study, FIDES-03, with the FGFR inhibitor derazantinib. The multi-cohort study is evaluating derazantinib in patients with advanced gastric cancer with FGFR genetic aberrations. Derazantinib will be assessed as monotherapy and in combination with other cancer treatments, for instance with Roche’s PD-L1 checkpoint inhibitor, atezolizumab. Basilea will be the sponsor of the study and Roche will provide clinical supply of atezolizumab. Dr. Marc Engelhardt, Basilea’s Chief Medical Officer, said: “Our development strategy for derazantinib is focused on strengthening the clinical evidence on the differentiation versus other FGFR inhibitors. The unique kinase inhibition profile of derazantinib, results from preclinical studies and the safety and tolerability profile observed in clinical studies, provide a strong rationale for evaluating the drug candidate in patient

Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA)28.9.2020 07:00:00 CESTPress release

Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years59% of infants were able to sit without support for at least 5 seconds No new safety signals were identifiedIn August, the FDA approved Evrysdi for the treatment of SMA in adults and children 2 months and older Basel, 28 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy (SMA). The 2-year results in infants treated with the therapeutic dose of Evrysdi (17/21) showed that they continued to improve and achieve motor milestones. This exploratory analysis showed that an estimated 88% of infants were alive and required no permanent ventilation at two years. In addition, at two years, 59% (10/17 vs. 7/17 at 1-year) of infants were able to sit without support for at least 5 seconds, assesse

HALF-YEAR RESULTS 2020: UNIBAIL-RODAMCO-WESTFIELD N.V.25.9.2020 20:00:00 CESTPress release

Amsterdam, September 25, 2020 Press Release HALF-YEAR RESULTS 2020: UNIBAIL-RODAMCO-WESTFIELD N.V. On September 25, 2020, Unibail-Rodamco-Westfield N.V. (“URW NV”) announced its 2020 half-year results and released its consolidated interim financial statements for the period ending June 30, 2020, which can be found on: https://www.urw-nv.com/en/investors/press-releases https://www.urw-nv.com/en/investors/press-releases and as an attachment to this press release. URW NV and its consolidated entities, together with Unibail-Rodamco-Westfield SE (“URW SE”) and its consolidated entities, form Unibail-Rodamco-Westfield (“URW”). URW SE consolidates URW NV and its controlled undertakings, and its 2020 half-year results represent a comprehensive overview of URW, and is available on: https://www.urw.com/en/investors/financial-information/financial-results https://www.urw.com/en/investors/financial-information/financial-results For further information, please contact: Investor Relations Media Rela